This HTML5 document contains 77 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://linked.opendata.cz/resource/drugbank/drug/DB00765/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00765/identifier/kegg-compound/
n11http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00765/identifier/pubchem-compound/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00765/identifier/pubchem-substance/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00765/identifier/kegg-drug/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00765/identifier/drugbank/
n8http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB00765/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00765/identifier/chemspider/
n16http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n10http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n22http://www.drugs.com/cdi/
n18http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00765
rdf:type
n3:Drug
n3:description
An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed)
n3:dosage
n6:271B5C27-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
3.4 to 3.7 hours
n3:indication
For use in the treatment of patients with pheochromocytoma, for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma.
n3:manufacturer
n5:271B5C25-363D-11E5-9242-09173F13E4C5
owl:sameAs
n8:DB00765 n27:DB00765
dcterms:title
Metyrosine
adms:identifier
n13:46506079 n14:PA450487 n15:441350 n21:390103 n23:D00762 n24:0006-0690-68 n25:DB00765 n26:C07921
n3:mechanismOfAction
Metyrosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines and their synthesis. This consequently, depletes the levels of the catecholamines dopamine, adrenaline and noradrenaline in the body,usually measured as decreased urinary excretion of catecholamines and their metabolites. One main end result of the catecholamine depletion is a decrease in blood presure.
n3:packager
n5:271B5C22-363D-11E5-9242-09173F13E4C5 n5:271B5C23-363D-11E5-9242-09173F13E4C5 n5:271B5C24-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.
n3:synonym
(-)-alpha-Methyl-L-tyrosine Metirosina alpha-Methyl-L-P-tyrosine alpha-Methyl-para-tyrosine Metirosinum Metyrosine (S)-alpha-Methyltyrosine Metirosin L-alpha-Methyltyrosine Methyltyrosine Métirosine Metirosine alpha-Methyl-P-tyrosine alpha-Methyltyrosine
n3:toxicity
Signs of metyrosine overdosage include those central nervous system effects observed in some patients even at low dosages. At doses exceeding 2000 mg/day, some degree of sedation or feeling of fatigue may persist. Doses of 2000-4000 mg/day can result in anxiety or agitated depression, neuromuscular effects (including fine tremor of the hands, gross tremor of the trunk, tightening of the jaw with trismus), diarrhea, and decreased salivation with dry mouth. The acute toxicity of metyrosine was 442 mg/kg and 752 mg/kg in the female mouse and rat respectively.
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Metyrosine.htm
n10:hasConcept
n11:M0329127
foaf:page
n18:metyrosine.htm n22:metyrosine.html
n3:IUPAC-Name
n4:271B5C2C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5C32-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5C31-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5C2E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5C2F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5C30-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5C42-363D-11E5-9242-09173F13E4C5 n4:271B5C2A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5C44-363D-11E5-9242-09173F13E4C5 n4:271B5C2B-363D-11E5-9242-09173F13E4C5 n4:271B5C28-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5C29-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n20:C02KB01
n3:H-Bond-Acceptor-Count
n4:271B5C38-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5C39-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5C33-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5C34-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5C36-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5C35-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5C37-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed from the gastrointestinal tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
672-87-7
n3:category
n3:containedIn
n16:271B5C26-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5C3E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5C40-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5C41-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5C43-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5C3D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5C3C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5C3F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5C2D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5C3A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5C3B-363D-11E5-9242-09173F13E4C5